Anti-CD20 monoclonal antibody
Ublituximab
Brand names: Briumvi
Adult dose
Dose: 450mg IV at week 0, 24 weeks then every 24 weeks
Route: IV
Frequency: q24w (after loading)
Clinical pearls
- Relapsing MS
- Specialist neurology; pre-medicate; HBV screening
Contraindications
- Active hepatitis B
- Active serious infection
- Severe immunodeficiency
- Pregnancy
- Hypersensitivity
Side effects
- Infusion reactions
- Infections
- HBV reactivation
- Hypogammaglobulinaemia
- Cytopenias
- PML (rare class)
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- Immunoglobulins
- Infections
- HBV
Reference: BNF; NICE TA958; SmPC; https://bnf.nice.org.uk/drugs/ublituximab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Drugs
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS